Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Characteristics Associated With Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence

Richter, Holly E.; Amundsen, C. L.; Erickson, S. W.; Jelovsek, J. E.; Komesu, Y.; Chermansky, C.; Harvie, H. S.; Albo, M.; Myers, D.; Gregory, W. T.; Wallace, D.for the NICHD Pelvic Floor Disorders Network

Obstetrical & Gynecological Survey: December 2017 - Volume 72 - Issue 12 - p 709–711
doi: 10.1097/01.ogx.0000527551.60666.74

(Abstracted from J Urol 2017;198:890–896)

Primary treatment approaches for women with urgency urinary incontinence (UUI) include medications and behavioral therapy. Patients with UUI refractory to primary treatments may be offered third-line treatment options such as sacral neuromodulation (SNM) or onabotulinumtoxinA.

University of Alabama at Birmingham, Birmingham, AL (H.E.R.); Duke University, Durham (C.L.A.); RTI International, Research Triangle Park (S.W.E., D.W.), NC; Cleveland Clinic, Cleveland, OH (J.E.J.); University of New Mexico, Albuquerque, NM (Y.K.); Magee-Women's Research Institute, University of Pittsburgh, Pittsburgh (C.C.); University of Pennsylvania, Philadelphia (H.S.H.), PA; University of California–San Diego, San Diego, CA (M.A.); Brown University, Providence, RI (D.M.); and Oregon Health and Science University, Portland, OR (W.T.G.)

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.